Article Sidebar
Views pdf: 32
TREATMENT OUTCOMES OF CHRONIC MYELOID LEUKEMIA IN THE CHRONIC PHASE TREATED WITH IMATINIB AT THE NATIONAL INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION IN THE PERIOD 2019 - 2023
Main Article Content
Abstract
Objective: To evaluate the treatment efficacy of Imatinib in patients with Philadelphia chromosome - positive CML during the period from 2019 to 2023 at the National Institute of Hematology and Blood Transfusion (NIHBT). Subjects and Methods: A descriptive study was conducted on 798 patients diagnosed with chronic phase Philadelphia-positive CML from January 1, 2019, to December 31, 2023. All patients were treated with Imatinib for a minimum duration of 3 months at the NIHBT. Results: The complete hematologic response (CHR) rate after 3 months of treatment was 87.61%. The cytogenetic response rates were 32.7% at 3 months, 43.5% at 6 months, and 64.3% at 12 months. The rates of major molecular response (MMR) were 22.2% after 3 months, 33% after 6 months, and 54.7% after 12 months. The rates of drug resistance and intolerance were 35.7% and 11.3%, respectively. Conclusion: Imatinib remains an effective treatment option for patients with chronic phase CML.
Article Details
Keywords
Chronic Myeloid Leukemia, Philadenphia, BCR - ABL, Imatinib.
References
2. Hughes TP, Hochhaus A, Branford S, Muller MC, Kaeda JS, Foroni L, et al. Long-term prognostic significance of early molecular response to Imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood. 2010;116(19):3758–65 [EuropePMCfree article] [Abstract] [Google Scholar].
3. Hướng dẫn chẩn đoán và điều trị bệnh lý huyết học (2022), Bộ y tế.
4. Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020; 34:966-84.
5. K. Chansung, C. Sirijerachai, A. Lekhakula và cộng sự (2016). Nilotinib As Second-Line Therapy in Patients with Chronic Myeloid Leukemia in Chronic Phase: Thailand Experience. Blood, 128 (22), 5448-5448.
6. Nguyễn Thị Mỹ Hòa, (2011). Đánh giá hiệu quả thuốc ức chế men protein tyrosine kinase (Imatinib mesylatee) trong điều trị bệnh bạch cầu mạn dòng tủy, Luận án tiến sĩ y học, trường Đại học Y Dược Thành phố Hồ Chí Minh.
7. Pfirrmann M, Baccarani M et al. Prognosis of long - term survival considering desease - specific dealth in patients with chronic myeloid leukemia. Leukeumia 2015. Article in press.
8. Aziz Z., Iqbal J., Akram M., et al (2007). “Treatment of chronic myeloid leukemia in the Imatinib era. Perspective from a developing country”. Cancer.109, pp. 1138 – 1145.
9. Aleksandra Golos et al. Deep molecular response on Imatinib treatment - results from a real - life retrospective study. Acta Haematologica Polonica 2021; Number 5, Volume 52, pages 504 - 508.
10. Long-term outcome following Imatinib therapy for chronic myelogenous leukemia, with assessment of dosage and blood levels: The JALSG CML202 study - PubMed (nih.gov).